Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...

An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

Data from a phase Ia clinical trial of an oral, long-acting integrase inhibitor (GS-1720) in development for HIV demonstrated ...

Gilead Sciences has announced new data from its pivotal Phase III PURPOSE 2 trial providing further details on the efficacy, ...

Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...

Insights speaks directly to the people with an inside track on the big issues. Here, Dan Glass demands pharmaceutical company ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, ...

Newly presented results include data on adherence to and pharmacokinetics of lenacapavir among trial participants. The data were presented during an oral abstract session at the International ...